IDenta Corp. (IDTA)
USD 0.36
(0.0%)
USD 0.36
(0.0%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 662.97 Thousand USD | -32.38% |
| 2022 | 983.39 Thousand USD | -3.8% |
| 2021 | 1.02 Million USD | 16.32% |
| 2020 | 878.8 Thousand USD | 35.57% |
| 2019 | 648.24 Thousand USD | 9.4% |
| 2018 | 592.56 Thousand USD | 102.97% |
| 2017 | 291.94 Thousand USD | 86.05% |
| 2016 | 156.91 Thousand USD | -13.15% |
| 2015 | 180.67 Thousand USD | 69.58% |
| 2014 | 106.54 Thousand USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 250.43 Thousand USD | -29.28% |
| 2024 Q1 | 354.11 Thousand USD | 36.97% |
| 2023 FY | 664.99 Thousand USD | -32.38% |
| 2023 Q4 | 258.53 Thousand USD | 109.01% |
| 2023 Q3 | 123.69 Thousand USD | 6.12% |
| 2023 Q1 | 167.52 Thousand USD | -52.92% |
| 2023 Q2 | 116.56 Thousand USD | -30.42% |
| 2022 Q2 | 243.38 Thousand USD | 78.4% |
| 2022 FY | 983.39 Thousand USD | -3.8% |
| 2022 Q4 | 355.83 Thousand USD | 46.43% |
| 2022 Q3 | 243 Thousand USD | -0.15% |
| 2022 Q1 | 136.42 Thousand USD | -53.24% |
| 2021 Q3 | 195.54 Thousand USD | -29.51% |
| 2021 Q2 | 277.39 Thousand USD | 7.88% |
| 2021 FY | 1.02 Million USD | 16.32% |
| 2021 Q4 | 291.74 Thousand USD | 49.19% |
| 2021 Q1 | 257.12 Thousand USD | 109.83% |
| 2020 Q4 | 122.54 Thousand USD | -67.58% |
| 2020 FY | 878.8 Thousand USD | 35.57% |
| 2020 Q1 | 180.06 Thousand USD | 26.85% |
| 2020 Q2 | 201.51 Thousand USD | 11.91% |
| 2020 Q3 | 377.94 Thousand USD | 87.56% |
| 2019 Q3 | 199.33 Thousand USD | 12.83% |
| 2019 Q1 | 131.38 Thousand USD | -28.31% |
| 2019 FY | 648.24 Thousand USD | 9.4% |
| 2019 Q4 | 141.95 Thousand USD | -28.78% |
| 2019 Q2 | 176.66 Thousand USD | 34.47% |
| 2018 Q3 | 199.15 Thousand USD | 89.07% |
| 2018 FY | 592.56 Thousand USD | 102.97% |
| 2018 Q4 | 183.25 Thousand USD | -7.98% |
| 2018 Q2 | 105.33 Thousand USD | -13.24% |
| 2018 Q1 | 121.41 Thousand USD | 66.51% |
| 2017 FY | 291.94 Thousand USD | 86.05% |
| 2017 Q1 | 110.81 Thousand USD | 0.0% |
| 2017 Q2 | 52.77 Thousand USD | -52.37% |
| 2017 Q3 | 54.2 Thousand USD | 2.71% |
| 2017 Q4 | 72.91 Thousand USD | 34.53% |
| 2016 FY | 156.91 Thousand USD | -13.15% |
| 2015 FY | 180.67 Thousand USD | 69.58% |
| 2014 FY | 106.54 Thousand USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| American Bio Medica Corporation | -193 Thousand USD | 443.51% |
| Arrayit Corporation | 2.57 Million USD | 74.254% |
| Atlantic International Corp. | -154.23 Thousand USD | 529.85% |
| Biocept, Inc. | -2.58 Million USD | 125.677% |
| Bioqual, Inc. | 7.42 Million USD | 91.076% |
| CardioGenics Holdings Inc | - USD | -Infinity% |
| DermTech, Inc. | 276 Thousand USD | -140.208% |
| Global WholeHealth Partners Corporation | - USD | -Infinity% |
| Hangzhou Tigermed Consulting Co., Ltd. | 6.73 Billion USD | 99.99% |
| HTG Molecular Diagnostics, Inc. | 1.79 Million USD | 63.047% |
| iMD Companies, Inc. | -23.63 Thousand USD | 2904.819% |
| Interpace Biosciences, Inc. | 23.04 Million USD | 97.123% |
| Integrative Health Technologies, Inc. | 77.57 Thousand USD | -754.669% |
| InVitro International | 635.98 Thousand USD | -4.244% |
| Lumos Diagnostics Holdings Limited | 6.56 Million USD | 89.898% |
| Many Bright Ideas Technologies Inc. | - USD | -Infinity% |
| Medical Imaging Corp. | 1.09 Million USD | 39.326% |
| NovelStem International Corp. | 12 Thousand USD | -5424.792% |
| Optigenex Inc. | -102.96 Thousand USD | 743.878% |
| PharmChem, Inc. | 3.9 Million USD | 83.02% |
| Proteome Sciences plc | 2.09 Million USD | 68.379% |
| Response Genetics, Inc | 3.94 Million USD | 83.182% |
| Rennova Health, Inc. | 6.26 Million USD | 89.423% |
| RushNet, Inc. | 1.1 Million USD | 39.981% |
| ScreenPro Security Inc. | 856.57 Thousand USD | 22.602% |
| Stella Diagnostics Inc. | - USD | -Infinity% |
| StageZero Life Sciences Ltd. | -403.74 Thousand USD | 264.206% |
| Todos Medical Ltd. | 4.31 Million USD | 84.618% |